Fasken Martineau DuMoulin LLP advised the sole agent and sole bookrunner. On July 4, 2022, Algernon Pharmaceuticals Inc. (CNSX:AGN) announced the closing of its previously announced marketed…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
